Science Simplified!

Comment

Comment by Dr. Krishna Kumari Challa 42 minutes ago

Why do some people react so badly to mosquito bites? The answer lies in mosquito saliva
Mosquito saliva contains anticoagulant and immune-modulating proteins that trigger histamine release and a Th2-type inflammatory response, causing itching, redness, and swelling. Reaction severity varies with immune genetics, age, prior exposure, and mosquito species; hypersensitivity can cause large local reactions. Saliva may also enhance establishment of mosquito-borne infections.

Comment by Dr. Krishna Kumari Challa 47 minutes ago

Overuse of inhalers found to increase heart attack risk in asthma and COPD patients

Overuse of reliever inhalers is associated with higher risks of developing and dying from cardiovascular disease, including heart failure, heart attack and ischemic stroke, in patients with asthma and COPD, according to a study published this week in ERJ Open Research.
In asthma and COPD, greater short-acting bronchodilator use was associated with higher cardiovascular disease and mortality risk. Use of ≥3 inhalers annually increased mortality versus ≤2; risks were greater in those without prior cardiovascular disease. Overuse may indicate poorly controlled disease requiring treatment review.
These "reliever" inhalers can help people breathe more easily when their symptoms are particularly bad. However, it is possible to overuse them if a patient's asthma or COPD is not being managed well by "preventer" treatments.
The study assessed real-world data from primary and secondary care for more than 280,000 COPD and asthma patients who used either SABA (short-acting beta-agonist), SAMA (short-acting muscarinic antagonist), both or no short-acting bronchodilators to manage their condition. Researchers took into account differences in age, sex, socioeconomic status, smoking history, nursing home residency, disease severity and other conditions or medications.

Both SABA and SAMA bronchodilators are often used as reliever therapies by asthma and COPD patients. SABA bronchodilators increased the risk of death by 12% and 14% in asthma and COPD patients, respectively, compared with no use. The risk of death from SAMA bronchodilators increased by 73% and 36%, respectively.

The researchers also assessed how the number of inhalers used per year affected cardiovascular health. They found that using three or more inhalers per year for either bronchodilator was associated with an increased risk of death compared with two or fewer inhalers per year. Patients who did not have any prior history of cardiovascular disease were found to be more vulnerable to cardiovascular problems resulting from inhaler overuse.
Overuse of short-acting bronchodilators is an alarm signal that indicates uncontrolled airway inflammation and requires a medical review of treatment. It should prompt patients to have their lungs checked and health care providers to check adherence and inhaler technique against treatment guidelines.
Patients should be informed that short-acting bronchodilators only relax airway muscles briefly. Uncontrolled asthma and COPD are already linked to an increased risk of cardiovascular disease and death. When this is combined with overuse of SABA and SAMA bronchodilators—which both cause faster, irregular heart rates as a side effect—these risks become even more pronounced. Overreliance on this short relief may allow the underlying disease activity to progress unchecked. This research should draw clinicians' attention to the fact that overuse is common and may be associated with adverse effects, even in patients without cardiac history.

Overuse of inhalers found to increase heart attack risk in asthma and COPD patients, ERJ Open Research (2026). DOI: 10.1183/23120541.00462-2026

Comment by Dr. Krishna Kumari Challa 57 minutes ago

Electrically charged raindrops could be corroding metal with protective coatings

Water droplets acquire 0.2–2 nC charges after sliding on common natural and synthetic surfaces. After 3,000 charged droplets contacted Teflon-coated copper, the coating degraded and underlying copper corroded; uncharged droplets caused no detectable damage. This mechanism may affect protective coatings on outdoor metal structures.

Zhongyuan Ni et al, Spontaneously charged water drops induce corrosion, Nature (2026). DOI: 10.1038/s41586-026-10941-6

Comment by Dr. Krishna Kumari Challa 1 hour ago

Scented cleaners can create nanoparticles that reach deep into the lungs within minutes, tiny-home experiment finds

What does a clean room smell like? Many people say citrus, pine, or flowers because these fragrances are common in cleaning products. A research team found that scent compounds in cleaning products—conventional and botanical essential oil-based—quickly react in the air, forming nanoparticles that can travel deep into the lungs if inhaled.
Researchers showed that indoor ozone reactions with fragrances from cleaning produce nanoparticles that carry a respiratory dose comparable to or greater than what you would experience from standing outside along a busy road.
The particles are different in terms of their composition, but the total dose can be higher. You're not seeing smoke, dust or haze in the air. Instead, you think the air smells great, so it must be clean.

To reduce exposure to this invisible pollution, the team suggests using unscented products, running exhaust fans, and avoiding ozone-generating devices while cleaning.
Steps to cut exposure
The researchers want these findings to inform consumers' choices, not alarm them, and provides several steps people can take to reduce their exposure while cleaning:

Choose low-fragrance or fragrance-free products.
Avoid applying several scented products in the same cleaning session.
Run exhaust fans or open windows to ventilate the space.
Do not simultaneously clean surfaces with scented products while using ozone-generating devices, such as far UV-C lamps.
Importantly, cleaning removes viruses and bacteria from surfaces, but it can also generate invisible air pollution. There's no visible dust or smoke in the air, but these particles are forming.

acs.digitellinc.com/live/37/session/591663

Comment by Dr. Krishna Kumari Challa 1 hour ago

Cell therapy substantially reduces severe rheumatoid arthritis in first clinical trial

Rheumatoid arthritis is a chronic disease in which the immune system mistakenly attacks the body's own joints. This causes recurrent inflammation and joint swelling and, as the disease progresses, can lead to joint damage. Currently available treatments can usually keep the inflammation under control but do not cure the disease. Patients therefore require lifelong medication, including anti-inflammatory drugs and medications that suppress the immune system, with all the associated side effects.

In some patients, even several of the newer treatments fail to produce an adequate response. Doctors then call the disease treatment-refractory. For those affected, this means persistent pain, restricted mobility and a substantial impact on quality of life.
One reason could be disease-driving B cells—memory cells of the adaptive immune system that may survive in the lymph nodes, bone marrow or joint tissue after an infection, where they produce harmful antibodies directed against the body's own tissues and repeatedly reignite the inflammation

Immunotherapies such as CAR T-cell therapy are used primarily to treat cancer. In the future, these patient-specific therapies, manufactured from patients' own immune cells, could also help cure autoimmune diseases. Six patients with particularly severe rheumatoid arthritis have now received this treatment at Charité—Universitätsmedizin Berlin. In the journal Nature Medicine, the researchers report the results from the world's first clinical trial of its kind: Disease activity decreased substantially in all participants. By the end of the observation period, three of the patients no longer required any medication for rheumatoid arthritis.
The researchers hope that CAR T cells, patients' own immune cells genetically modified in the laboratory, could selectively track down the disease-driving B cells, even deep within tissues, reset the pathological B-cell memory as fully as possible and thereby effectively give the B-cell system a fresh start.
Originally developed for cancer treatment, CAR T cells are now being used more widely. In cancer treatment, patients' immune cells are given a kind of "training" to specifically recognize and eliminate tumour cells; in autoimmune diseases, the aim is instead to direct immune cells toward disease-driving memory cells.

Fredrik N. Albach et al, CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial, Nature Medicine (2026). DOI: 10.1038/s41591-026-04603-3

Comment by Dr. Krishna Kumari Challa 2 hours ago

El Niños have been more intense over the last 40 years than in the previous 1,000 years, coral records reveal

El Niño is a natural phenomenon that, every few years, causes the tropical Pacific to become warmer than usual. Under normal conditions, trade winds blow along the equator from east to west. This pushes warm water from South America toward Australia. But when the trade winds weaken, warm water spreads eastward, back toward South America, kicking off an El Niño event.
The atmospheric circulation responds as heavy rainfall shifts from Indonesia into the central Pacific, leaving the western Pacific in drought. This weakens the trade winds further, locking in El Niño conditions that can persist for one to two years. These temperature and precipitation fluctuations originate in the tropical Pacific, but they affect weather all over the world.
For instance, storm tracks over the U.S. shift southward, bringing more rain to the desert Southwest and less to the Northwest. Similar shifts around the world lead to droughts and flooding that bring disease, crop failure, wildfires and other crises that affect people's health and well-being.
The question is not whether the current El Niño will happen, but how bad it is going to be, and how bad the impacts will be? This event now is superimposed on global warming, and it's likely to supercharge the temperature increase that we would normally see from greenhouse gases. There are forecasts that we might get as hot as 1.7 or 1.8 degrees Celsius above preindustrial temperatures, which is quite a bit higher than the current record.

As an El Niño of historic proportions is taking shape in the tropical Pacific now, a new study has found that El Niño events have become nearly 40% stronger in the last 40 years than they were in the preindustrial era.
In fact, the study, which examined modern and ancient corals in the Galápagos Islands, found that El Niño events in the last four decades were stronger than any in the 1,000 years before about 1850, when humans began affecting the climate with greenhouse gases.
We don't see a time in the past where El Niños have been as strong as today, and researchers show that the strength of El Niño changes in parallel with warming global temperatures.
These findings tell us that the big El Niño events of the last 40 years are not normal in the context of the last thousand years.

J.E. Cole, Recent strengthening of eastern Pacific ENSO is unprecedented in the last millennium paleorecord, Science (2026). DOI: 10.1126/science.ady2660. www.science.org/doi/10.1126/science.ady2660

Comment by Dr. Krishna Kumari Challa yesterday

The team tested their approach with about 100 positive bloodstream infection samples donated by patients and stored at Penn State Hershey Medical Center's clinical microbiology laboratory. The researchers found that combining these techniques offered comprehensive diagnosis in as little as seven hours, enabling confident identification of the infection-causing pathogen from whole blood.
They also integrated antibiotic susceptibility testing into the same process, providing physicians with the information needed to select the most appropriate treatment.

Siew Chin et al, Rapid and robust diagnosis of bloodstream infections by single-cell analysis, Science Advances (2026). DOI: 10.1126/sciadv.aeh3580. www.science.org/doi/10.1126/sciadv.aeh3580

Part 2

Comment by Dr. Krishna Kumari Challa yesterday

New approach cuts sepsis diagnosis from days to hours

Sepsis, a life-threatening condition that stems from the body trying to fight off an infection, plagues millions of people worldwide, with one in three deaths recorded in hospitals attributed in part to sepsis. Despite the severity of the condition, which can kill in as little as 12 hours, it takes between two and seven days for most traditional approaches to definitively identify sepsis-causing bacteria in blood infections.
A research team has developed a way to condense the days long diagnosis timeline to just hours. The new approach rapidly grows the bacteria present in collected blood samples, intermittently analyzing the samples with advanced techniques that help scientists identify the specific pathogens causing infection.
With a bloodstream infection, it is critical to find and neutralize the cause as quickly as possible before it triggers a septic response from the body.
Physicians must not only detect the presence of bacteria—they must also identify the specific pathogens, as well as the best antibiotic for treatment. The dire stakes of a false positive or negative complicate this further, as every hour counts when treating a bloodstream infection.
Many different bacteria can cause sepsis, and they may respond differently to treatment. Therefore, analysis must be thorough to ensure the best treatment is prescribed.
To identify the bacteria causing a bloodstream infection, current best practices require bacterial culturing: blood samples are enriched over a few days so that bacteria present grow to measurable levels. Then, technicians further analyze the samples to identify the specific bacteria, a process that adds another day or two to diagnosis.

Researchers now report in a paper published in Science Advances that their approach facilitated faster diagnosis and could help clinical decision-making that avoids worsening antibiotic resistance in the bacterial strains causing infections.
To accelerate diagnosis without sacrificing accuracy, the team had to rethink culturing. Traditionally, bacterial growth in a cultured blood sample is measured through the carbon dioxide released by the bacteria. When this change in carbon dioxide levels confirms the presence of pathogens, bacteria are separated from the blood sample and analyzed.

The team's new approach, called STREAM, fast-tracks this culturing by facilitating rapid bacterial growth while isolating and analyzing the pathogens simultaneously—blood samples are mixed in a specialized "broth" that separates whole blood cells from the individual bacteria found in the sample during culturing.

Molecular analysis, a process known formally as barcoding, allows the team to detect tiny fragments of genetic information from isolated bacteria. From these smaller samples collected intermittently during culturing, the researchers can identify the specific bacterial species present.

These smaller samples are then subjected to a series of new, single-cell-based techniques that allow researchers to analyze a bacterium with microscopic imaging. These images are then analyzed by computer algorithms the team developed to eliminate visual clutter, helping physicians determine the specific bacteria causing infection. These analyses also suggest which antibiotics the strain is susceptible to and any existing antibiotic resistance the strain may have.

Part 1

Comment by Dr. Krishna Kumari Challa yesterday

Most vaccines work by prompting the body to make antibodies, which bind to part of a pathogen—the outside of a virus, say—and neutralize it before it can cause infection. Antibodies and the B cells that produce them can then linger in the blood for years, lying in wait for their targets.

But in the case of Zika virus vaccines, antibodies pose a big problem. Zika belongs to a family of mosquito-borne viruses—the orthoflaviviruses—that also includes dengue and Japanese encephalitis virus, and these viruses overlap across much of the world. Zika and dengue are especially close cousins: The envelope proteins that coat them are so similar that antibodies raised against one routinely latch onto the other.
The researchers studied a phenomenon called antibody-dependent enhancement (ADE). When antibodies bind a virus without disabling it—because they were raised against a relative or because their levels have waned—they can end up ferrying the virus into immune cells instead of blocking it, driving a more severe infection. Because of ADE, a person who receives a vaccine that prompts the body to make antibodies against Zika virus could be vulnerable to a severe case of Zika or dengue infection later on.

The risk of ADE means vaccine researchers need to find innovative ways of protecting the body from orthoflaviviruses.
In past studies, the rsearchers uncovered the potential power of T cells in fighting orthoflaviviruses. T cells patrol the body for signs of disease and adapt over time to recognize specific threats, and vaccines can train them just as they train antibodies. They have shown that T cells offer a chance to fight these viruses when you can't depend on antibodies.
In their tests, the unmodified vaccine got the immune system to fight Zika virus infection with a double whammy of antibodies and T cells. Transferring CD8+ T cells from those mice into unvaccinated animals cut Zika levels on its own—so T cells were pulling real weight even in the vaccine whose antibodies worked as intended.

The fusion-loop mutant vaccine came with an even bigger surprise. Its antibodies shared many features with those from the unmodified vaccine in cell cultures and test tubes, but they did not protect unvaccinated animals at all. Stripping out the CD8+ T cells, by contrast, wiped the protection away. "This vaccine wasn't protecting via antibodies," says Shresta. "It was protecting via T cells."

"The protection came from CD8+ T cells, a type of immune cell that finds and destroys virus-infected cells.
This protection was effective, but it didn't last. Twelve weeks after the final dose, mice given the fusion-loop mutant vaccine were no better off than unvaccinated animals, while those given the unmodified vaccine were still protected. The lesson is a cautionary one: A change made to reduce ADE risk quietly cost the vaccine its staying power.

A Zika virus vaccine with E protein fusion loop mutations protects via CD8+ T cells, Nature Microbiology (2026). DOI: 10.1038/s41564-026-02465-6

Part 2

**

Comment by Dr. Krishna Kumari Challa yesterday

Experimental Zika vaccine reveals T cells can drive protection without antibodies

Zika virus is carried by different species of Aedes mosquitoes. These mosquitoes had spread into new regions and found new victims. More people were getting sick, including pregnant women.

Doctors around the world realized that increased cases of microcephaly (significantly reduced head and brain development) in newborns were caused by Zika virus infection. Women who contracted Zika virus during pregnancy were also much more likely to miscarry. Babies who survived could be born with eye and ear problems and joint issues, a pattern of birth defects doctors now group together as congenital Zika syndrome.

Today, at least 97 countries and territories have reported evidence of Zika virus transmission, according to the WHO. Reported cases have fallen sharply since 2017, but researchers expect the pool of susceptible people to rebuild over the coming decade, and a warming climate and the spread of insecticide-resistant Aedes mosquitoes keep widening the map of who is at risk. We still do not have specific Zika virus treatments or vaccines.
Researchers published a study in Nature Microbiology showing that an experimental Zika virus vaccine can protect mice through T cells alone, without help from virus-fighting antibodies. The catch: On their own, those T cells do not keep the protection going.

This discovery is a critical step in the fight against Zika virus and its close viral relatives, including the life-threatening dengue virus.
Part 1

• ‹ Previous
• 1
• 2
• 3
• …
• 1285
• Next ›
• Page